Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-20

Study Completion Date

2016-05-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have undergone endovascular revascularization for moderate to severe claudication or ischemic rest pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia

NCT02230527

Peripheral Arterial Disease

TERMINATED PHASE2/PHASE3

A Pilot Study To Examine The Effects Of Ticagrelor To Protect Against Type 2 Diabetes-Induced Vascular Damage

NCT02214654

Type 2 Diabetes Mellitus； Stable Coronary Disease

UNKNOWN

The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery

NCT02352402

Coronary Artery Disease Stable Angina Acute Coronary Syndrome

UNKNOWN PHASE3

Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.

NCT01226602

Blood Flow Speed Coronary Flow Velocity

COMPLETED PHASE1

Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina

NCT02284048

Microvascular Angina

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients with Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Artery Disease (PAD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ticagrelor

26 Weeks of ticagrelor 90mg twice a day plus aspirin placebo once daily

Group Type EXPERIMENTAL

Ticagrelor

Intervention Type DRUG

Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.

Aspirin

26 Weeks of aspirin 100mg once daily plus ticagrelor placebo twice a day

Group Type ACTIVE_COMPARATOR

Comparator

Intervention Type DRUG

Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ticagrelor

Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.

Intervention Type DRUG

Comparator

Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Brilinta Aspirin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written informed consent prior to any study specific procedures.
2. Ambulatory male or female outpatients aged 50 years of age or older at the time of the Screening Visit.
3. EVR, below the inguinal ligament that includes the distal SFA and/or popliteal and/or tibial arteries, that is planned to occur within 5 weeks after the Screening Visit, as determined and clearly documented by the Principal Investigator or physician Sub-Investigator (MD/DO). Patients undergoing a proximal revascularization may be enrolled as long as their procedure also includes treating the distal SFA, popliteal or tibial arteries. The EVR must be confirmed as technically successful (a completed procedure where haemostasis has been achieved) before the patient is randomised.
4. Normal inflow into the lower extremity as determined by the Principal Investigator or physician Sub-Investigator (MD/DO). Adequacy of inflow can be assessed by hemodynamic measures, angiography or other imaging modalities obtained during Screening or recorded in the medical records up to 30 days prior to the Screening Visit or as defined by imaging at the time of the procedure. A patient with inadequate inflow at the time of Screening can still be enrolled if the inflow is addressed and resolved by the planned revascularization procedure.
5. Diagnosis of PAD confirmed by history and any one of the following observed in the index (intervention) leg at the Screening Visit:

1. Resting ABI ≤0.90, or
2. In patients with an ABI \> 1.40 (non-compressible vessels) a resting GTI \<0.70 can be used for inclusions.
6. Patient has been advised of the beneficial effects of smoking cessation and exercise therapy but is not in the process of changing their smoking status or exercise at the time of the Screening Visit.

Exclusion Criteria

1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
2. Revascularisation planned only to treat proximal (inflow) disease in the iliac and/or common femoral arteries.
3. Previous randomisation in the present study.
4. Participation in another clinical study with an investigational product within the last 3 months or any new clinical trial during the course of this study.
5. Gangrene or ischemic ulcer of either lower extremity.
6. PAD of a non-atherosclerotic nature.
7. Clinical necessity to use dual antiplatelet therapy within 7 days prior to randomisation, or single anti-platelet therapy (ticlopidine, prasugrel, vorapaxar, ticagrelor or dipyridamole) other than clopidogrel or aspirin. Clopidogrel or aspirin can be taken up to and including the time that the loading dose is being given.
8. Clinical necessity to use the following restricted concomitant medications within 4 weeks prior to randomisation. Patients taking any of these medications at the Screening Visit may be considered for randomisation after a 4 week washout period from the medication.

1. Pentoxifylline or cilostazol for relief of claudication symptoms
2. Chronic oral or parenteral anticoagulant therapy (greater than 7 days)
3. Strong inhibitors of CYP3A enzymes (Section 5.6.9.1)
4. Strong inducers of CYP3A enzymes (Section 5.6.9.2)
5. Simvastatin or lovastatin at daily doses over 40 mg
9. Any disease process (e.g. angina, cardiac abnormality, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), respiratory disease, obesity, stroke, severe neuropathy of the foot, symptomatic musculoskeletal disease of the lower extremity), other than PAD, that would interfere with exercise performance during the ETT or prevent the patient from reaching their claudication-limited PWT as the primary endpoint of the study.
10. Coronary, aortic surgery, angioplasty, lumbar sympathectomy or lower extremity surgery that impacts the ability to walk on a treadmill within the past 3 months prior to EVR. Revascularization of the non-index lower extremity within the past 4 weeks prior to EVR.
11. Any major lower limb amputation due to PAD anticipated within the next 3 months or prior major amputation due to PAD (minor toe amputations allowed if it does not interfere with ambulation).
12. Myocardial infarction or stroke in the previous 3 months.
13. Any concomitant disease process with a life expectancy of less than 1 year or which is sufficiently severe as to compromise the validity of test performance.
14. Dementia likely to jeopardise understanding of information pertinent to study conduct or compliance to study procedures.
15. Concern for the inability of the patient to comply with study procedures and/or followup (e.g., alcohol or drug abuse).
16. Resting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥95 mmHg at the Screening Visit, in spite of antihypertensive treatments allowed by the protocol.
17. A known bleeding diathesis, haemostatic or coagulation disorder, or systemic bleeding, whether resolved or ongoing.
18. Known severe liver disease (e.g., ascites and or clinical signs of coagulopathy).
19. Renal failure requiring dialysis.
20. History of previous intracranial bleed at any time, gastrointestinal bleed within the past 6 months, or major surgery within 30 days (if the surgical wound is judged to be associated with an increased risk of bleeding).
21. History of thrombocytopenia or neutropenia.
22. Hypersensitivity to ticagrelor, aspirin or lactose.
23. Initiation of antidiabetic, antihypertensive, lipid-lowering and beta-blocking drugs within 1 month prior to the Screening Visit.
24. Pregnancy, lactation, fertility without protection against pregnancy (for women of childbearing potential; a urine or serum pregnancy test will be performed at the Screening Visit).

Minimum Eligible Age

50 Years

Maximum Eligible Age

130 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No